BT-20
Zellname |
Beschreibung |
Bestell-Nr. |
Einheit |
Preis, Euro |
|---|---|---|---|---|
BT-20 |
Humane Brust Karzinom Zell-Linie |
300130 |
cryovial |
265,00 |
BT-20 |
Humane Brust Karzinom Zell-Linie |
330130 |
vital |
335,00 |
| Designation: | BT-20 |
| Depositor: | Lasfargues |
| Organism: | Homo sapiens (human) |
| Ethnicity: | Caucasian |
| Age/Stage: | 74 years old |
| Gender: | female |
| Tissue: | Breast |
| Morphology: | epithelial |
| Celltype: | mammary gland |
| Growth Properties: | monolayer |
| Description: | This breast tumor line was established by E.Y. Lasfargues and L. Ozzello in 1958 by isolation and cultivation of cells spilling out of the tumor when it was cut in thin slices. A mycoplasma contaminant was discovered and eliminated early in 1972. Growth of BT-20 cells is inhibited by tumor necrosis factor alpha (TNF alpha). BT-20 cells are negative for estrogen receptor, but do express an estrogen receptor mRNA that has deletion of exon 5. |
| Culture Medium: | DMEM:Ham's F12 mixture (1:1) supplemented with 2 mM L-glutamine and 10% fetal bovine serum |
| Subculturing: | Remove medium and rinse with 0.02% EDTA (versene) solution. Add fresh 0.025% trypsin/0.02% EDTA (versene) solution, remove and let the culture sit at 37oC until the cells detach. Add fresh medium, remove trypsin by centrifugation and dispense into new flasks. Subculture every 6 to 8 days. |
| Split Ratio: | A ratio of 1:2 to 1:4 is recommended |
| Fluid Renewal: | 2 to 3 times weekly |
| Freeze Medium: | CM-1 (CLS Cell Lines Service) |
| Sterility: | Tests for mycoplasma, bacteria and fungi were negative |
| Biosafety Level: | 1 |
| Tumorigenic: | yes, in nude mice; forms grade II adenocarcinomas |
| Oncogene: | wnt4 +; wnt7h + |
| Karyotype: | modal number = 50, many markers with large subtelocentrics most characteristic; (P87) Hyperdiploid with abnormalities including fragmented chromosomes, breaks, secondary constrictions, translocations, submetacentric and telocentric markers |
| Antigen Expression: | HLA A1, Bw16 (+/-) |
| Isoenzymes: | PGM3, 1; PGM1, 1; ES-D, 1; AK-1, 1-2; G6PD, B; GLO-1, 1-2; Phenotype Frequency Product: 0.0115 |
| Reverse Transcriptase: | negative |
References: Lasfargues EY, Ozello L. Cultivation of human breast carcinomas. J Natl Cancer Inst 21(6): 1131-1147, 1958. Ozello L, Lasfargues EY, Murray MR. Growth-promoting activity of acid mucopolysaccharides on a strain of human mammary carcinoma cells. Cancer Res 20: 600-604, 1960. Fogh J et al. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. 58: 209-214, 1977. Pollack MS et al. HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines. J Natl Cancer Inst 66: 1003-1012, 1981. Sugarman BJ et al. Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science 230: 943-945, 1985. Lan MS et al. Polypeptide core of a human pancreatic tumor mucin antigen. Cancer Res 50: 2997-3001, 1990. Castles CG et al. Expression of a constitutively active estrogen receptor variant in the estrogen receptor-negative BT-20 human breast cancer cell line. Cancer Res 53: 5934-5939, 1993. Huguet EL et al. Differential expression of human Wnt genes 2, 3, 4, and 7B in human breast cell lines and normal and disease states of human breast tissue. Cancer Res 54: 2615-2621, 1994. Littlewood-Evans AJ et al. The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res 57: 5386-5390, 1997. Geiger T et al. Antitumor activity of a PKC-alpha antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice. Anticancer Drug Des 13: 35-45, 1998. Rhodes A, Jasani B, Couturier J, McKinley MJ, Morgan JM, Dodson AR, Navabi H, Miller KD, Balaton AJ. A formalin-fixed, paraffin-processed cell line standard for quality control of immunohistochemical assay of HER-2/neu expression in breast cancer. Am J Clin Pathol 117(1):81-9, 2002. Kammerer U, Thanner F, Kapp M, Dietl J, Sutterlin M. Expression of tumor markers on breast and ovarian cancer cell lines. Anticancer Res. 23(2A): 1051-5,2003. Asaga S, Ueda M, Jinno H, Kikuchi K, Itano O, Ikeda T, Kitajima M. Identification of a new breast cancer-related gene by restriction landmark genomic scanning. Anticancer Res. 26(1A): 35-42,2006. | |
